## **Supplementary Material**

## miR-101a-3p Impairs Synaptic Plasticity and Contributes to Synucleinopathy



**Supplementary Figure 1** miRNAome changes revealed in midbrain of [A30P]  $\alpha$ syn mice by small-RNA-seq. a) Pie chart depicting average percentages of the different RNA classes detected in the small RNA libraries as a readout for quality of the sequencing technique; b) Principal component analysis (PCA) plots showing the clustering of Wt (orange) and Tg (green); c) Table of the top interacting miRNAs according to number of confirmed target genes, including log2 fold change and number of reads; d) Enrichment ratio of overrepresented Gene Ontology terms of upregulated and downregulated miRNA targets; e) Real time qPCR validation of miR-543-3p levels in Wt (n = 8) and Tg (n = 7) mouse midbrain; f) List of the top 10 downregulated miR-101a-3p target genes Shisa6 and Dag1 levels in Wt (n = 8) and Tg (n = 7) mouse midbrain



Supplementary Figure 2. Lentiviral induction of miR-101a-3p *in vitro*. a) Quantification of infected neurons in mass primary cultures expressed as the percentage of GFP positive cells to total neuron number and a representative image of infected mass cultures (infection with control vector is depicted); GFP - green; MAP2 - red; scale bar = 50 µm. b) Quantification of GFP levels in infected neurons by immunoblotting analysis and representative immunoblots. c) Quantification of  $\alpha$ -syn levels in infected neurons by immunoblotting analysis and representative immunoblots. All data are expressed as mean ± SEM; Student's t-test; \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001)



**Supplementary Figure 3.** Dendritic spine classification. a) Representative Golgi-Cox staining image of the analyzed brain region in Tg mouse; brightfield; scale bar =  $200 \ \mu m$ ; b) Magnification of dendritic spine segment with classification to mushroom, thin and stubby; brightfield; scale bar=  $10 \ \mu m$ ; c) Magnification of dendritic spine segment *in vitro* with classification to mushroom, thin and stubby; MAP2 - red; scale bar=  $10 \ \mu m$ 

Case Number	NBTR Number	Diagnosis	age	gender	PMD	рН	Braak NFT	LBs	Other pathologies
26383	19830263	Control	76	F	24	6.11	0	No	-
30783	19830307	Control	93	F	10	6.27	III	No	Primary visual infarct
98089	19890980	Control	85	М	23	#	Ι	-	-
87887	19870878	Control	81	F	32	6.23	-	-	-
96288	19880962	Control	34	F	103	#	-	-	-
103688	19881036	Control	79	F	26	6.4	-	-	-
103689	19891036	Control	79	F	26	6.4	II	-	-
5690	19900056	Control	51	М	25	#	-	-	-
1991	19910019	Control	54	М	12	#	-	-	-
22991	19910229	Control	53	М	12	#	-	-	-
29391	19910293	Control	65	F	17	#	0	-	-
31991	19910319	Control	67	М	36	6.56	-	-	-
2793	19930027	Control	84	F	7	6.55	IV	-	-
5095	19950050	DLB	76	F	23	6.03	II	Neocortical	-
20292	19920202	DLB	66	М	31	6.54	0	Limbic	-
10498	19980104	DLB	86	М	41	6.08	II	Neocortical	-
13798	19980137	XCBD	85	М	39	6.23	II	No	-
131 96	19960131	DLB	77	F	23	6.24	IV	Neocortical	-
703	20030007	DLB	88	F	16	5.92	III	Neocortical	Right cerebellar infarct
10504	20040105	PDD/DLB	68	Μ	11	6.15	V	Neocortical	-

## Supplementary Table 1. Human samples

Supplementary rapid 2. 1 miller	upplementary Table 2. Prime	r List
---------------------------------	-----------------------------	--------

Primers	5'-3' Sequence/ID	Company
Actb forward	GCG AGA AGA TGA CCC AGA TC	Metabion
Actb reverse	CCA GTG GTA CGG CCA GAG G	Metabion
<i>Gabrb2</i> forward	GCC TGC ATG ATG GAC CTA AG	Metabion
Gabrb2 reverse	CCT GTG GAG AAA ACA ACT TTC TTG	Metabion
Dlgap3 forward	GCT CCT CCT TCA ACT TCA GA	Metabion
Dlgap3 reverse	GGA CTG GCT CGG GGT GG	Metabion
Dag1 forward	TTG ACA GGG TAG ATG CCT GG	Metabion
Dag1 reverse	ATA CAT GAG CTG GCT GTT GG	Metabion
Shisa6 forward	AGT TCG AGT GCA ACA ACA GC	Metabion
Shisa6 reverse	AGT TGG TCT TGT CCT TCT CC	Metabion
Hs_RNU6-2_11 miScript Primer Assay	MS00033740	Qiagen
Mm_miR-101a_3 miScript Primer Assay	MS00011011	Qiagen